Rochester, NY 6/17/2009 11:12:04 PM
Afternoon Losers NASDAQ - STSI,JAZZ,ETFC - Sourced WhisperFromWallStreet.com
Star Scientific, Inc. - Jazz Pharmaceuticals, Inc. - E*TRADE Financial Corporation
Afternoon Losers NASDAQ - STSI,JAZZ,ETFC - Sourced WhisperFromWallStreet.com
WhisperfromWallStreet.com is an award winning newsletter that specializes in sending alerts to our subscribers on stocks we think are going to run, why we think so, and teaching you how to become a better trader. We can now even deliver this information instantly to our "Penny Stock Alert" gadget that sits right on your Microsoft Vista or iGoogle desktop. You will know from the instant you get your confirmation email that we are different. What do you have to lose except a little time and a chance to really learn how to make money trading.
Sign up for our FREE alerts at WhisperfromWallStreet.com
---
Star Scientific, Inc.,STSI
1.04 Down 3.17 (75.30%) 11:59am ET
Star Scientific, Inc., together with its subsidiaries, engages in the development, implementation, and licensing of tobacco curing technology that prevent the formation of carcinogenic toxins present in tobacco and tobacco smoke, primarily the tobacco-specific nitrosamines (TSNAs). It also manufactures, sells, markets, and develops low-TSNA dissolvable smokeless tobacco products, such as ARIVA, a compressed powdered tobacco cigalett pieces; and STONEWALL Hard Snuff, a non-fermented spit-free hard tobacco product for moist snuff users designed to provide adult tobacco users with an alternative to cigarettes.
Last Trade: 0.98
Day's Range: 0.83 - 1.03
52wk Range: 1.06 - 5.89
Volume: 30,960,780
---
Jazz Pharmaceuticals, Inc.,JAZZ
3.24 Down 0.55 (14.51%) 11:55am ET
Trading in shares of Jazz Pharmaceuticals cooled a bit, down 15% at $3.21. The stock has shot up about 300% over the past 30 days on positive news flow for its fibromyalgia treatment sodium oxybate.
ABOUT
Jazz Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes products for neurology and psychiatry primarily in the United States. The company's marketed products include Xyrem for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy; and Luvox CR for obsessive compulsive disorder and social anxiety disorder. Its product candidate in Phase III clinical trials comprise JZP-6 for the treatment of fibromyalgia.
Last Trade: 3.17
Day's Range: 3.02 - 3.77
52wk Range: 0.52 - 8.95
Volume: 1,732,222
---
Here are a few alerts our WhisperfromWallStreet.com subscribers enjoyed.
SPNG 1000%
AMNG 241%
RKBD 300%
UTRM 169%
TLLE 266%
Sign up to receive free stock alerts
---
E*TRADE Financial Corporation,ETFC
1.42 Down 0.23 (13.94%) 12:04pm ET
E*Trade Financial is raising $1.2 billion through the sale of common stock and a "significant" debt exchange as part of the online brokerage's plans to raise capital.
ABOUT
E*TRADE Financial Corporation, through its subsidiaries, provides online brokerage and related products and services primarily to individual retail investors, under the brand name of E*TRADE Financial worldwide. It offers various brokerage products and services, including automated order placement and execution of the U.S. and international equities, currencies, futures, options, exchange-traded funds, mutual funds, and bonds.
Last Trade: 1.41
Day's Range: 1.37 - 1.50
52wk Range: 0.59 - 4.05
Volume: 45,420,987
---
Disclaimer: Full disclaimer at http://whisperfromwallstreet.com/disclaimer.php
WhisperfromWallStreet.com (WFWS) based upon information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by WFWS to be accurate, and should not be considered to be all-inclusive. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. WFWS is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.whisperfromwallstreet.com or mentioned herein. WFWS may have been compensated with shares or with cash from third party shareholders or the company on behalf of one or more of the companies mentioned in this opinion.
This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a companies' annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and WFWS undertakes no obligation to update such statements.
This is not a solicitation to buy or sell any securities. WhisperfromWallStreet.com, nor any of its affiliates are not registered investment advisors or a broker dealers. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment.
CONTACT: WhisperFromWallStreet.com
